Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-03
2006-10-03
Siew, Jeffrey (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07115556
ABSTRACT:
The present invention relates to variant forms of human prolactin which act as antagonists at the prolactin receptor, and to the use of such variants in the treatment of human cancers and proliferative disorders, including both benign and malignant diseases of the breast and prostate.
REFERENCES:
patent: 5350863 (1994-09-01), Kuekenhoehner et al.
patent: 5506107 (1996-04-01), Cunningham et al.
patent: 5681809 (1997-10-01), Kopchick et al.
patent: 6429186 (2002-08-01), Fuh et al.
patent: WO 92/21029 (1992-11-01), None
patent: WO 94/19004 (1994-09-01), None
Burgess et al., J of Cell Bio. 111:2129-2138, 1990.
Bowie et al. Science, 247:1306-1310, 1990.
Nicoll et al (Endocr Rev 1986 7:169-203).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
(MSNBC News Services, “Mixed results on new cancer drug”, Nov. 9, 2000).
Gura (Science, 1997, 278:1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Curti (Crit. Rev. in Oncology/Hematology, 1993, 14:29-39).
Chen et al (International Journal of Oncology, 2002, 20: 813-818).
Straub et al (1993, J Biol Chem 268(29): 21997-20003).
Kouklis et al (1993, J Cell Science, 106(pt 3): 919-28).
Bontenbal, Feasibility, Endocrine and Anti-Tumour Effects of a Triple Endocrine Therapy with Tamoxifen, a Somatostatin Analogue and an Antiprolactin in Post-menopausal Metastatic Breast Cancer: a Randomized Study with Long-Term Follow-up, 1998, Br. J. Cancer 77:115-122.
Chen, Development of Recombinant Human Prolactin Receptor Antagonists by Molecular Mimicry of the Phosphorylated Hormone, 1998, Endocrinol 139:609-616.
Nevalainen, Prolactin and Prolactin Receptors are Expressed and Functioning in Human Prostate, 1997, J. Clin. Invest. 99: 618-627.
Nevalainen, Androgen-Dependent Expression of Prolactin in rat Prostate Epithelium in vivo and in organ Culture, 1997, FASEB J. 11: 1297-1307.
Ormandy, Coexpression and Cross-Regulation of the Prolactin Receptor and Sex Steroid Hormone Receptors in Breast Cancer, 1997, 3. Clin. Endocrinol. Metab. 82: 3692-369.
Reynolds, Expression of Prolactin and its Receptor in Human Breast Carcinoma, 1997, Endocrinology 138: 5555-5560.
Wennbo, Transgenic Mice Overexpressing the Prolactin Gene Develop Dramatic Enlargement of the Prostate Gland, 1997, Endocrinol. 138: 4410-4415.
Janssen, In Vitro Characterization of Prolactin-Induced Effects on Pro4feration in the Neoplastic LNCaP, DU145, and PC3 Models of the Human Prostate, 1996, Cancer 77: 144-149.
Goffm et al, Antagonistic Properties of Human Prolactin Analogs that Show Paradoxical Agonistic Activity in the Nb2 Bioassay, 1996, J. Biol. Chem. 271: 16573-16579.
Baumann, Editorial: Growth Hormone Binding Protein-Errant Receptor or Active Player?, 1995, Endocrinol. 136: 377-378.
Clevenger, Expression of Prolactin and Prolactin Receptor in Human Breast Carcinoma, 1995, Am. J. Pathol. 146:695-705.
Chen, Amino Acid Residues in the Third x-Helix of Growth Hormone Involved in Growth Promoting Activity, 1995, Mol. Endocrin, 9:292-302.
Fuh and Wells, Prolactin Receptor Antagonists that Inhibit the Growth of Breast Cancer Cell Lines, 1995, J. Biol. Chem. 270:13133-13137.
Ginsburg, Prolactin Synthesis and Secretion by Human Breast Cancer Cells, 1995, Cancer Res. 55:2591-2595.
Oliver, New Directions with Hormone Therapy in Prostate Cancer: Possible Benefit from Blocking Prolactin and Use of Hormone Treatment Intermittently in Combination with Immunotherapy, 1995, Eur. J. Cancer 31A:859-860.
Horseman, Editorial: Prolactin, Proliferation, and Protooncogenes, 1995, Endocrinol., 136: 5249-5251.
Bartke, Neuroendocrine and Reproductive Consequences of Overexpression of Growth Hormone in Transgenic Mice, 1994, Proc. Soc. Exp. Biol. Med. 206:345-359.
Baumann et al., Growth Hormone-Binding Proteins: State of the Art, 1994, J. Endocrinol. 141:1-6.
Chen, In Vitro and In Vivo Studies of Antagonistic Effects of Human Growth Hormone Analogs 1994, J. Biol. Chem. 269:15892-15897.
Costello, Effect of Prolactin on the Prostate ,1994, Prostate 24:162-166.
Goffin, Evidence for a Second Receptor Binding Site on Human Prolactin, 1994, J. Biol. Chem. 269:32598-32606.
Horseman, Transcriptional Regulation by the Helix Bundle Peptide Hormones: Growth Hormone, Prolactin, and Hematopoietic Cytokines, 1994, Endocrin. Rev. 15:627-649.
Fields, Detection of Prolactin Messenger RNA in Mammary and other Normal and Neoplastic Tissues by Polymerase Chain Reaction, 1993, Lab Invest. 68:354-360.
Fuh, Mechanism-Based Design of Prolactin Receptor Antagonists, 1993, J. Biol. Chem. 268:5376-5381.
Kelly, The Growth Hormone/Prolactin Receptor Family, 1993, Recent Prog. Horm. Res. 48:123-164.
Wang and Walker, Dephosphorylation of Standard Prolactin Produces a More Biologically Active Molecular: Evidence for Antagonism between Nonphosphoiylated and Phosphorylated Prolactin in the Stimulation of Nb2 Cell Proliferation, 1993, Endocrinol. 133:2156-2160.
Wells, The Molecular Basis for Growth Hormone-Receptor Interactions, 1993, Recent Prog. Hormone Res. 48:253-275.
Amit et al., Growth-Hormone-Binding Protein in Patients with Acromegaly, 1992, Hormone Res. 37:205-211.
Fuh, Rational Design of Potent Antagonists to the Human Growth Hormone Receptor, 1992, Science 256:1677-1680.
Krown, Prolactin Isoform 2 as an Autocrine Growth Factor for GH3 Cells, 1992, Endocrinol, 131:595-602.
Baumann, Growth Hormone Binding Proteins: Biochemical Characterization and Assays, 1991, Acta Endocrinol. 124 (Suppl. 2):21-26.
Chen, Glycine 119 of Bovine Growth Hormone is Critical for Growth-Promoting Activity, 1991, Mol. Endocrinol. 5:1845-1852.
Cunningham et al., Rational Design of Receptor-Specific Variants of Human Growth Hormone, 1991, Proc. Natl. Acad. Sci. USA 88:3407-3411.
Hochberg, The Effect of Human Growth Hormone Therapy on GH Binding Protein in GH-Deficient Children, 1991, Acta Endocrinol. 125:23-27.
Kelly, The Prolactin/Growth Hormone Receptor Family, 1991, Endocrin Rev. 12:235-25 1.
Chen, Expression of a Mutated Bovine Growth Hormone Gene Suppresses Growth of Transgenic Mice, 1990, Proc. Natl. Acad. Sci. USA 87:5061-5065.
Clevenger, Regulation of Interleukin2-Driven T-Lymphocyte Proliferation by Prolactin, 1990, Proc. Natl. Acad. Sci USA 87:6460-6464.
Cunningham, Engineering Human Prolactin to Bind to the Human Growth Hormone Receptor, 1990, Sci. 247:1461-1465.
Biswas, Role of Serum in the Prolactin Responsiveness of MCF- 7 Human Breast Cancer Cells in Long-Term Tissue Culture, 1987, Cancer Res. 47:3509-35 14.
Shiu, Biological Actions of Prolactin in Human Breast Cancer, 1987, Recent Prog. Horm. Res. 43:277-303.
Manni, Promotion by Prolactin of the Growth of Human Breast Neoplasms Cultured in vitro in the Soft Agar Clonogenic Assay,1986, Cancer Res. 46:1669-1672.
Buckley, Prolactin is a Tumor Promoter in Rat Liver, 1985, Life Sci. 37:2569-2575.
Odoma, Evidence for the Association Between Blood Prolactin and Androgen Receptors in BPH, 1985,J.Uro1133:717-720.
Welsch, Host Factors Affecting the Growth of Carcinogen-Induced Rat Mammary Carconimas: A Review and Tribute to Charles Brenton Huggins, 1985, Cancer Res. 45:3415-3443.
Peyrat, Effect of Bromocriptin Treatment on Prolactin and Steroid Receptor Levels in Human Breast Cancer, 1984, Eur J. Cancer Clin. Oncol. 20:1363-1367.
Leake et al., Characterization of the Prolactin Receptor in Human Prostate, 1983, J. Endocrinol. 99:321-328.
Malarkey, Physiological Concentrations of Prolactin can Promote the Growth of Human Breast Tumor Cells in Culture, 1983, J. Clin. Endocrinol Metab. 56:673-677.
Saroff, Measurements of Prolactin and Androgens in Patients with Prostatic Diseases, 1980, Oncology 37:46-52.
Shiu and Friesen Mechanism of Action of Prolactin in the Control of Mammary Gland Function, 1980, Annu. Rev. Physiol. 42:83-96.
Hammond et al., Serum FSH, LH and Prolactin in Normal Males and Patients with Prostatic Diseases, 1977, Clin. Endocrinol. 7:129-135.
Harper, Plasma Steroid and Protein Hormone Concentrations in Patients with Prostatic Carcinoma, Before and During Oestrogen Therapy, 1976, Acta Endocrinol
Chen Wen Y.
Wagner Thomas E.
Foley & Lardner LLP
Goddard Laura B.
Greenville Hospital System
Siew Jeffrey
LandOfFree
Use of anti-prolactin agents to treat proliferative conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of anti-prolactin agents to treat proliferative conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of anti-prolactin agents to treat proliferative conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3631146